Divisadero Street Capital Management LP Decreases Stake in The Beauty Health Company (NASDAQ:SKIN)

Divisadero Street Capital Management LP lessened its stake in shares of The Beauty Health Company (NASDAQ:SKIN) by 47.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,577,078 shares of the company’s stock after selling 2,297,488 shares during the quarter. Divisadero Street Capital Management LP’s holdings in Beauty Health were worth $4,948,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in SKIN. HighMark Wealth Management LLC bought a new stake in Beauty Health during the 1st quarter valued at $31,000. Caprock Group LLC bought a new position in shares of Beauty Health during the second quarter valued at about $38,000. SageView Advisory Group LLC purchased a new stake in shares of Beauty Health during the first quarter worth about $60,000. Aigen Investment Management LP grew its stake in shares of Beauty Health by 88.7% in the fourth quarter. Aigen Investment Management LP now owns 31,865 shares of the company’s stock worth $99,000 after purchasing an additional 14,974 shares during the last quarter. Finally, 180 Wealth Advisors LLC increased its holdings in Beauty Health by 25.3% during the 2nd quarter. 180 Wealth Advisors LLC now owns 101,855 shares of the company’s stock valued at $187,000 after purchasing an additional 20,570 shares during the period. Institutional investors own 93.26% of the company’s stock.

Beauty Health Trading Up 1.3 %

NASDAQ SKIN opened at $1.53 on Friday. The stock’s 50 day moving average is $1.64 and its 200 day moving average is $2.51. The company has a quick ratio of 5.47, a current ratio of 6.49 and a debt-to-equity ratio of 7.96. The firm has a market capitalization of $189.75 million, a PE ratio of -2.18 and a beta of 0.95. The Beauty Health Company has a twelve month low of $0.91 and a twelve month high of $6.79.

Beauty Health (NASDAQ:SKIN) last announced its earnings results on Thursday, August 8th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). The business had revenue of $90.60 million for the quarter, compared to the consensus estimate of $98.46 million. Beauty Health had a negative net margin of 22.86% and a negative return on equity of 4.57%. Research analysts forecast that The Beauty Health Company will post -0.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Beauty Health

In other Beauty Health news, Chairman Brent L. Saunders bought 40,450 shares of the stock in a transaction dated Monday, August 12th. The stock was purchased at an average cost of $1.08 per share, for a total transaction of $43,686.00. Following the completion of the acquisition, the chairman now owns 5,921,769 shares of the company’s stock, valued at $6,395,510.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 41.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SKIN. Stifel Nicolaus dropped their price objective on Beauty Health from $4.00 to $2.00 and set a “hold” rating for the company in a report on Friday, July 26th. Canaccord Genuity Group dropped their price target on Beauty Health from $2.00 to $1.25 and set a “hold” rating for the company in a research note on Monday, August 12th. Finally, Piper Sandler reissued an “underweight” rating and set a $1.00 price objective (down from $1.50) on shares of Beauty Health in a research report on Friday, August 9th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Beauty Health presently has a consensus rating of “Hold” and an average target price of $2.46.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.